Spots Global Cancer Trial Database for oregovomab
Every month we try and update this database with for oregovomab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | NCT01959672 | Pancreatic Aden... Resectable Panc... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | 4-Dimensional C... Fluorouracil Gemcitabine Hyd... Laboratory Biom... Leucovorin Calc... Nelfinavir Mesy... Oregovomab Stereotactic Bo... Therapeutic Con... | 19 Years - | University of Nebraska | |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | NCT01616303 | Ovarian Neoplas... | Carboplatin Paclitaxel oregovomab | 18 Years - 75 Years | Quest PharmaTech Inc. | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer | NCT00004064 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy | NCT00003634 | Fallopian Tube ... Ovarian Cancer Primary Periton... | oregovomab | 18 Years - | National Cancer Institute (NCI) | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | NCT04498117 | Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop... | Oregovomab Paclitaxel Carboplatin Placebo Carboplatin | 18 Years - | CanariaBio Inc. | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | NCT01959672 | Pancreatic Aden... Resectable Panc... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | 4-Dimensional C... Fluorouracil Gemcitabine Hyd... Laboratory Biom... Leucovorin Calc... Nelfinavir Mesy... Oregovomab Stereotactic Bo... Therapeutic Con... | 19 Years - | University of Nebraska | |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | NCT03100006 | Epithelial Ovar... | Nivolumab Oregovomab | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | NCT03100006 | Epithelial Ovar... | Nivolumab Oregovomab | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer | NCT01959672 | Pancreatic Aden... Resectable Panc... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | 4-Dimensional C... Fluorouracil Gemcitabine Hyd... Laboratory Biom... Leucovorin Calc... Nelfinavir Mesy... Oregovomab Stereotactic Bo... Therapeutic Con... | 19 Years - | University of Nebraska | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer | NCT03162562 | Cancer of Ovary Neoplasms, Ovar... Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... Ovary Cancer | Oregovomab Poly ICLC | 18 Years - 90 Years | CanariaBio Inc. | |
| A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. | NCT05335993 | Recurrent Ovari... Recurrent Epith... Recurrent Epith... Recurrent Fallo... Peritoneal Canc... Recurrent Carci... Adenocarcinoma ... | Oregovomab Niraparib | 18 Years - 99 Years | CanariaBio Inc. | |
| Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | NCT04938583 | Ovarian Cancer ... Ovarian Cancer ... Ovarian Cancer ... | Oregovomab Bevacizumab Paclitaxel Carboplatin | 19 Years - | CanariaBio Inc. | |
| A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | NCT01616303 | Ovarian Neoplas... | Carboplatin Paclitaxel oregovomab | 18 Years - 75 Years | Quest PharmaTech Inc. | |
| Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy | NCT00551265 | Fallopian Tube ... Primary Periton... Recurrent Ovari... Stage III Ovari... Stage IV Ovaria... | Cyclophosphamid... Laboratory Biom... Oregovomab | 18 Years - | GOG Foundation | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Clinical Trial for Ovarian Cancer (OvaRex®) | NCT00050375 | Ovarian Cancer | oregovomab | 18 Years - | Unither Pharmaceuticals | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma | NCT00034138 | Ovarian Neoplas... | oregovomab | 18 Years - 65 Years | Unither Pharmaceuticals | |
| Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer | NCT05605535 | Ovarian Neoplas... Ovarian Cancer Fallopian Tube ... Peritoneal Carc... Ovarian Serous ... | Oregovomab Paclitaxel Carboplatin Placebo | 18 Years - | CanariaBio Inc. | |
| Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin | NCT04620954 | Epithelial Ovar... | Oregovomab Nivolumab Chemotherapy | 21 Years - | National Cancer Centre, Singapore |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
